Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arrowhead Research
Arrowhead subsidiary Insert Therapeutics to hire pharmaceutical executive as CEO
November 7th, 2006
Arrowhead Research Corp. (ARWR), announced that Edward Jacobs will be appointed CEO & president of its majority-owned subsidiary, Insert Therapeutics, on January 1, 2007. Until then, Jacobs will serve as a consultant to Insert. "Ed brings more than 20 years of executive level pharma and biotech experience, with particular emphasis in the oncology space, as well as strategic planning and marketing," said R. Bruce Stewart, Arrowhead's chairman. "He has successfully led several biotech companies to acquisition by major pharmaceutical companies and secured substantial collaborations and licensing deals. Now that Insert's anti-cancer drug candidate is in...
Source: Drug Law Weekly (2006-11-07)
|
